921 related articles for article (PubMed ID: 19740433)
1. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
2. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells.
Galliher AJ; Schiemann WP
Breast Cancer Res; 2006; 8(4):R42. PubMed ID: 16859511
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
Wendt MK; Smith JA; Schiemann WP
Oncogene; 2010 Dec; 29(49):6485-98. PubMed ID: 20802523
[TBL] [Abstract][Full Text] [Related]
4. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
Galliher AJ; Schiemann WP
Cancer Res; 2007 Apr; 67(8):3752-8. PubMed ID: 17440088
[TBL] [Abstract][Full Text] [Related]
5. Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Galliher-Beckley AJ; Schiemann WP
Carcinogenesis; 2008 Feb; 29(2):244-51. PubMed ID: 18174260
[TBL] [Abstract][Full Text] [Related]
6. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
[TBL] [Abstract][Full Text] [Related]
7. p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity.
Wendt MK; Smith JA; Schiemann WP
J Biol Chem; 2009 Dec; 284(49):34145-56. PubMed ID: 19822523
[TBL] [Abstract][Full Text] [Related]
8. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621
[TBL] [Abstract][Full Text] [Related]
10. Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells.
Taylor MA; Amin JD; Kirschmann DA; Schiemann WP
Neoplasia; 2011 May; 13(5):406-18. PubMed ID: 21532881
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta stimulates intestinal epithelial focal adhesion kinase synthesis via Smad- and p38-dependent mechanisms.
Walsh MF; Ampasala DR; Hatfield J; Vander Heide R; Suer S; Rishi AK; Basson MD
Am J Pathol; 2008 Aug; 173(2):385-99. PubMed ID: 18583311
[TBL] [Abstract][Full Text] [Related]
12. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
13. TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
Wendt MK; Schiemann BJ; Parvani JG; Lee YH; Kang Y; Schiemann WP
Oncogene; 2013 Apr; 32(16):2005-15. PubMed ID: 22710711
[TBL] [Abstract][Full Text] [Related]
14. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II.
Maeda M; Shintani Y; Wheelock MJ; Johnson KR
J Biol Chem; 2006 Jan; 281(1):59-68. PubMed ID: 16267045
[TBL] [Abstract][Full Text] [Related]
15. Twist induces epithelial-mesenchymal transition and cell motility in breast cancer via ITGB1-FAK/ILK signaling axis and its associated downstream network.
Yang J; Hou Y; Zhou M; Wen S; Zhou J; Xu L; Tang X; Du YE; Hu P; Liu M
Int J Biochem Cell Biol; 2016 Feb; 71():62-71. PubMed ID: 26693891
[TBL] [Abstract][Full Text] [Related]
16. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
17. TGF-β autocrine pathway and MAPK signaling promote cell invasiveness and in vivo mammary adenocarcinoma tumor progression.
Daroqui MC; Vazquez P; Bal de Kier Joffé E; Bakin AV; Puricelli LI
Oncol Rep; 2012 Aug; 28(2):567-75. PubMed ID: 22614218
[TBL] [Abstract][Full Text] [Related]
18. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
19. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
Matise LA; Palmer TD; Ashby WJ; Nashabi A; Chytil A; Aakre M; Pickup MW; Gorska AE; Zijlstra A; Moses HL
Breast Cancer Res; 2012 Jul; 14(4):R98. PubMed ID: 22748014
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
